Calcium (carbonate vs citrate) trials recruiting now
26 registrations that name calcium as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 26 registrations
Status
Phase
22US sites across 18 states
1
2 to 4
5 to 19
20 or more
All 26 registrations
RecruitingNCT05958342
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Phase 2
Jason Sperry
About 1,050 people
Started Jun 30, 2024
In plain words A Phase 2 study of calcium in people 18 to 90, run by Jason Sperry. It plans to enroll about 1,050 people at 18 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Trauma; Hemorrhage.
What it tests, as registered
Calcium Gluconate; Vasopressin; saline placebo
Registered summary
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.
Where, as registered
18 US sites in 14 states.
RecruitingNCT07217899
Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony
Phase 2
University of Michigan
About 140 people
Started Oct 20, 2025
In plain words A Phase 2 study of calcium in female participants 18 and older, run by University of Michigan. It plans to enroll about 140 people at 1 US site.
Viable Intrauterine Pregnancy, Gestational Age ≥24 weeks
Labor Converted to Cesarean Delivery at High Risk for Atonic Bleeding Defined as: Any exposure to oxytocin infusion for labor augmentation or induction prior to cesarean delivery
Or Scheduled Cesarean Delivery at High Risk for Atonic Bleeding Defined as scheduled Cesarean-Section (CS) plus any one of:
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Calcium Gluconate; Saline
Registered summary
This research study is being done to learn what effect a single dose of calcium gluconate will have on blood loss at the time of cesarean delivery in pregnancy patients at high risk for uterine atony.
Where, as registered
1 US site in 1 state.
RecruitingNCT06568315
Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal and Newborn Hemoglobin and Iron Status
Phase 3
Johns Hopkins Bloomberg School of Public Health
About 3,200 people
Started Aug 25, 2025
In plain words A Phase 3 study of calcium in female participants 15 and older, run by Johns Hopkins Bloomberg School of Public Health. It plans to enroll about 3,200 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 15 and older; healthy volunteers accepted. Conditions: Anemia, Iron Deficiency.
Burkina Faso: married or unmarried pregnant women aged ≥15 years
Pakistan: married pregnant women ≥18 years
Willing to receive all antenatal care at a study clinic
Willing to stop iron folic acid supplementation to receive the study intervention
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Concurrent multiple micronutrient and calcium supplementation; Separate multiple micronutrient and calcium supplementation
Registered summary
The World Health Organization (WHO) currently recommends the pregnant women receive iron-containing supplements and, in settings where calcium intake is low, calcium supplements. Supplements are to be taken at two separate times of the day as calcium may interfere with iron absorption. The goal of this clinical trial is to learn whether taking daily calcium supplements and iron-containing multiple micronutrient supplements together, at the same time, has any negative impact on the hemoglobin or iron status of pregnant women or the woman's infants. The full summary is on the listing.
Where, as registered
No US site; Burkina Faso (1), Pakistan (1).
RecruitingNCT06235749
Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery
No phase
Rambam Health Care Campus
About 1,180 people
Started Nov 14, 2023
In plain words A study of calcium in female participants 18 and older, run by Rambam Health Care Campus. It plans to enroll about 1,180 people at 4 sites, none in the US.
Postpartum hemorrhage (PPH) is the leading cause of death related to pregnancy. PPH can lead to blood transfusion, disseminated intravascular coagulation (DIC), hysterectomy, or death. The prophylactic administration of uterotonic agents as part of an active management of the third stage of labor has been proven to reduce rates of PPH. However, even with these treatments, PPH rate is still relatively high, and puts women at risk of heavy bleeding and death. Calcium is a key component in the coagulation cascade and known as factor IV. The full summary is on the listing.
Where, as registered
No US site; Israel (4).
RecruitingNCT07714902
Administration Of Calcium Gluconate for The Reduction of Blood Loss During Vaginal Delivery
No phase
Rambam Health Care Campus
About 710 people
Starts Jun 24, 2026 (estimated)
In plain words A study of calcium in male participants 18 and older, run by Rambam Health Care Campus. It plans to enroll about 710 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older; healthy volunteers accepted. Conditions: Postpartum Hemorrhage.
Gestational age of 37 weeks or more, and planning a vaginal delivery.
The exclusion criteria are on the listing.
What it tests, as registered
calcium gluconate; Normal saline placebo
Registered summary
Postpartum hemorrhage is one of the leading causes of maternal morbidity following childbirth. Even when excessive bleeding is not clinically recognized, some women experience a significant decrease in hemoglobin levels after delivery, which may result in anemia, fatigue, delayed recovery, and the need for additional medical treatment. Calcium plays an important role in uterine muscle contraction and blood clotting. Previous studies have suggested that calcium administration may help reduce blood loss after childbirth. The full summary is on the listing.
Where, as registered
No US site; Israel (1).
RecruitingNCT07867951
Comparison of Postoperative Pain After Double Antibiotic Paste vs Calcium Hydroxide in Teeth With Symptomatic Apical Periodontitis
No phase
College of Physicians and Surgeons Pakistan
About 662 people
Started Sep 5, 2025
In plain words A study of calcium in people 16 to 50, run by College of Physicians and Surgeons Pakistan. It plans to enroll about 662 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 16 to 50. Conditions: Symptomatic Apical Periodontitis.
This randomized controlled trial aims to compare the mean postoperative pain after using double antibiotic paste (DAP) versus calcium hydroxide (CH) as an intracanal medicament in teeth with symptomatic apical periodontitis. Symptomatic apical periodontitis is a painful dental condition caused by inflammation and destruction of the tissues around the root apex of a tooth. It is diagnosed clinically by a painful response to biting, percussion, or palpation, and radiographically by widening of the periodontal ligament space. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
RecruitingNCT05571514
Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis
No phase
Centre Hospitalier Universitaire de Saint Etienne
About 200 people
Started May 12, 2023
In plain words A study of calcium in female participants 50 to 65, run by Centre Hospitalier Universitaire de Saint Etienne. It plans to enroll about 200 people at 7 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 50 to 65. Conditions: Post Menopausal Osteoporosis.
Post-menopausal women (50-65y) with risk of becoming osteoporotic
T-score between -1 and -3
Absence of fragility fractures history
The exclusion criteria are on the listing.
What it tests, as registered
Mother-of-pearl; Calcium Carbonate
Registered summary
Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality. Given potential side effects, hormone replacement therapy is no longer recommended for menopausal women with risk of becoming osteoporotic. The very significant decrease in the use of these treatments is suspected of contributing to a resurgence in the incidence of osteoporotic fractures, particularly in women before the age of 70. There is a need for prevention of osteoporosis.
Where, as registered
No US site; France (7).
RecruitingNCT06660524
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
Phase 4
China National Center for Cardiovascular Diseases
About 196 people
Started Mar 1, 2024
In plain words A Phase 4 study of calcium in people 50 and older, run by China National Center for Cardiovascular Diseases. It plans to enroll about 196 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older. Conditions: Degenerative Heart Valve Disease; Heart Valve Calcification; Chronic Kidney Disease(CKD); Calcium-Phosphorus Metabolism Disorders.
Age ≥ 50 years old.
Degenerative valvular heart disease clearly diagnosed by ultrasound or clinical history with calcification manifestation (including no stenosis or insufficiency due to calcification, mild, moderate and severe stenosis and insufficiency…
The goal of this clinical trial is to learn if calcium-phosphorus regulation therapy can slow the progression of heart valve calcification in patients with degenerative heart valve disease and chronic kidney disease (CKD). The main questions it aims to answer are: * Does Sevelamer lower the progression of heart valve calcification compared to calcium carbonate over 12 months? * What are the impacts of calcium-phosphorus regulation therapy on major cardiovascular events such as heart failure, cardiovascular death, and the need for valve surgery? Researchers will compare Sevelamer to calcium… The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07543744
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
Phase 1
R-Pharm
About 180 people
Started Apr 17, 2025
In plain words A Phase 1 study of calcium in people 18 and older, run by R-Pharm. It plans to enroll about 180 people at 26 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Metastatic Colorectal Cancer.
A voluntarily signed and dated Informed Consent form (ICF) of the patient
Histologically verified (documented results of respective examinations available) metastatic colorectal adenocarcinoma (in case the results of previous examinations are not available, the diagnosis will be verified in the central…
Patient consent to undergo a screening biopsy if archival tissue samples are unavailable for histological diagnosis verification
Patients with metastatic colorectal cancer (mCRC), either de novo metastatic or recurrent with distant metastases, who are candidates for first-line therapy
9 more inclusion criteria and the exclusion criteria are on the listing.
The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI. The additional objective is to perform a pilot evaluation of the efficacy of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI.
Where, as registered
No US site; Russia (26).
RecruitingNCT07256769
Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis
Observational
Regina Elena Cancer Institute
About 134 people
Started Sep 29, 2025
In plain words An observational study of calcium in female participants 35 to 70, run by Regina Elena Cancer Institute. It plans to enroll about 134 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 35 to 70. Conditions: Osteoporosis Secondary; Breast Cancer Females.
caucasian women aged between 35 and 70;
diagnosed with breast cancer undergoing treatment with aromatase inhibitors or tamoxifen + GnRH analogues or aromatase inhibitors + GnRH analogues not started more than 12 months ago, about to start treatment with oral bone resorption…
vitamin D levels below 30 ng/ml (test carried out no more than 6 months prior to the baseline/T0 visit)
patients able to comply with the procedures and/or requirements of the study
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Group 1: calcium carbonate/cholecalciferol; Group 2: Synostea® (calcium carbonate/cholecalciferol/vitamin K/α-lactalbumin/ d-chiro-inositol)
Registered summary
In women with breast cancer undergoing adjuvant hormone therapy, the marked tissue hypoestrogenism induced by therapy with aromatase inhibitors and/or tamoxifen ± GnRH analogues causes a significant acceleration in bone mass loss, with a consequent increased risk of fracture from the first year of therapy. It is therefore essential to start treatment with antiresorptive drugs and calcium and vitamin D supplementation. It has been hypothesized that vitamin K and α-lactalbumin have an effect in improving the absorption of calcium and vitamin D. The full summary is on the listing.
Where, as registered
No US site; Italy (2).
RecruitingNCT07187544
Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery
No phase
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
About 120 people
Started Dec 1, 2025
In plain words A study of calcium in female participants 18 to 45, run by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. It plans to enroll about 120 people at 1 site, none in the US.
Scheduled CD for patients ≥ 37 weeks excluding high risk factors for uterine atony
Neuraxial anesthesia as the primary anesthetic where intrathecal medications are the primary anesthetic
The exclusion criteria are on the listing.
What it tests, as registered
Calcium Chloride; Placebo; Carbetocin
Registered summary
Postpartum hemorrhage (PPH) is a leading cause of maternal mortality, and its severity has been increasing globally, including in high-income countries. The most common cause of PPH is uterine atony occurring in about 70% of cases. Uterotonic agents, like oxytocin, are key in managing the third stage of labour to prevent PPH. Oxytocin is a short-acting medication and requires frequent dosing, however, carbetocin, a longer-acting analogue that can be administered as a single dose, provides sustained uterotonic activity. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07534852
NIMA-Colon Cancer Study
No phase
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
About 120 people
Started Jul 1, 2025
In plain words A study of calcium in people 18 to 75, run by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Colon Cancer.
Adults aged 18 to 75 years.
Male and female participants.
Diagnosis of colon cancer at localized or locally advanced stages (TNM stages I-III).
Patients scheduled for primary surgical treatment.
The exclusion criteria are on the listing.
What it tests, as registered
Standard hypercaloric-hyperproteic nutritional supplementation; HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium; Supervised exercise program; General physical activity recommendations
Registered summary
The goal of this study is to evaluate the effects of nutritional supplementation and physical activity interventions on recovery, muscle strength, nutritional status, inflammation, and metabolic health in adults with colon cancer undergoing surgery. Patients with colon cancer frequently experience loss of muscle mass, reduced physical function, and nutritional deterioration both before and after surgery, which may adversely affect recovery and quality of life. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT07571837
Modulation of Periapical Inflammation Following Nano-sized Intracanal Medication. A Randomized Controlled Clinical Trial
No phase
Al-Azhar University
About 63 people
Started Oct 8, 2026
In plain words A study of calcium in male participants 20 to 40, run by Al-Azhar University. It plans to enroll about 63 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 20 to 40. Conditions: Post-operative Pain; Periapical Inflammation.
The main cause of endodontic disorders is microbial infection. From the infected pulp tissue, microorganisms can penetrate into the deeper layers of root dentine and propagate a periapical tissue through the apical foramen and lateral canals causing apical periodontitis. Apical periodontitis is an inflammatory condition affecting the periapical area of teeth with a global prevalence of 52% among individuals and 5% at tooth level. At the periapical region, microbes and their products encounter the host immune defense. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07641933
Biological, Radiographic and Clinical Evaluation of Various Inter-Visit Root Canal Dressings in Retreatment Cases
Phase 1
Ain Shams University
About 60 people
Started Jun 1, 2026
In plain words A Phase 1 study of calcium in people 21 to 45, run by Ain Shams University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 45; healthy volunteers accepted. Conditions: Intervention Studies; ASA Physical Status I; Intracanal Medication; Periapical Abscess; Retreatment.
Age: 21-45 years.
Medically free patients. (ASA Class 1)
Gender: males and females
Patients who are cooperative at operation and in attendance at scheduled follow-up visits.
2 more inclusion criteria and the exclusion criteria are on the listing.
The aim of this clinical trial is to evaluate anti-inflammatory effect of various intracanal medications: 1. Calcium Hydroxide Slurry mixed with 3% Sodium Hypochlorite 2. Calcium Silicate 3. Calcium Hydroxide In retreatment cases in terms of: 1. Biological Evaluation: Biomarker (IL 1B) 2. Radiographic Evaluation: CBCT 3. Clinical Evaluation: Pain Score (VAS)
Where, as registered
No US site; Egypt (1).
RecruitingNCT06531278
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Phase 2
Jiang Long
About 40 people
Started Jul 16, 2024
In plain words A Phase 2 study of calcium in people 18 to 75, run by Jiang Long. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Pancreatic Cancer Metastatic to Liver.
Patients voluntarily join this study and sign the informed consent form
Age: 18-75 years old (inclusive), male or female
Histologically confirmed pancreatic cancer liver metastases and no previous treatment of any systemic anti-swelling tumor treatment
No central nervous system metastases
6 more inclusion criteria and the exclusion criteria are on the listing.
1. Evaluation of adebelimab in combination with irinotecan liposomes, oxaliplatin, fluorouracil, efficacy and safety of leucovorin in the first-line treatment of advanced metastatic pancreatic cancer 2. Construct the model of immunotherapy combined with chemotherapy for the treatment of pancreatic cancer liver metastasis
Where, as registered
No US site; China (1).
RecruitingNCT06478238
Calcium Folinate Treatment of Spastic Paraplegia 56
Early phase 1
Shanghai 6th People's Hospital
About 10 people
Starts Jul 1, 2024 (estimated)
In plain words An early phase 1 study of calcium in people of any age, run by Shanghai 6th People's Hospital. It plans to enroll about 10 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people of any age. Conditions: Hereditary Spastic Paraplegia.
Patients meet the clinical diagnostic standard of hereditary spastic paraplegia (HSP);
Spastic paraplegia type 56 (SPG56) was diagnosed by CYP2U1 pathogenic mutation;
Patients are willing to participate in clinical trials and able to understand and comply with the research program.
The exclusion criteria are on the listing.
What it tests, as registered
calcium folinate
Registered summary
SPG56 is one of the complicated and early-onset HSP subtypes caused by genetic mutations in CYP2U1. So far, there is no standardized and specific clinical therapy for SPG56. The goal of this clinical trial is to explore the efficacy and safety of calcium folinate in the treatment of SPG56 patients. This study is prospective, open-label and single arm and this trial will last for 6 years. A total of 10 patients will participate and they will receive calcium folinate treatment and professional clinical evaluation regularly.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07763509
Calcium-Rich Food Versus Calcium Carbonate for Bone Health
No phase
Cornell University
About 217 people
Starts Sep 1, 2026 (estimated)
In plain words A study of calcium in female participants 40 to 90, run by Cornell University. It plans to enroll about 217 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 90; healthy volunteers accepted. Conditions: Osteopenia; Osteoporosis; Bone Health in Perimenopausal Women; Menopause Related Conditions; Fracture Healing.
What it tests, as registered
500 mg calcium from milk-derived minerals; Calcium Carbonate 500 MG
Registered summary
This study will compare adherence, tolerability, safety, and treatment satisfaction between a calcium-rich food and a traditional calcium carbonate supplement in women ages 40 to 90 who are at increased risk for osteoporosis. Participants will be randomly assigned to receive either a calcium-rich food providing 500 mg of calcium from milk-derived minerals or a 500 mg calcium carbonate supplement once daily for four weeks. Participants will complete brief weekly questionnaires assessing supplement use, gastrointestinal symptoms, and treatment satisfaction. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07876843
The Effectiveness of a Weight-dependent Algorithm for Dosing Vitamin D.
No phase
Atlantic Health System
About 200 people
Starts Jan 1, 2027 (estimated)
In plain words A study of calcium in people 6 to 21, run by Atlantic Health System. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 21; healthy volunteers accepted. Conditions: Hypovitaminosis D.
1\. 6 to 21 years old (inclusive) 2. Patients 63.5 kg (140 lbs) and up 3. Patients not currently taking vitamin D supplements
The exclusion criteria are on the listing.
What it tests, as registered
Vitamin D3, Calcium, and Vitamin C
Registered summary
Vitamin D is essential for calcium absorption and bone growth, brain development, and immune system function. Vitamin D is produced by the body in response to natural sunlight. In New Jersey, which is not near the equator and where children are indoors for large parts of the year or use of sun block, it is possible that otherwise healthy children may suffer from vitamin D deficiency, placing them at risk for weak bones, fractures and poor bone growth. Larger children are at a higher risk of deficiency. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07760948
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
Phase 2
Vanderbilt University Medical Center
About 90 people
Starts Dec 1, 2026 (estimated)
In plain words A Phase 2 study of calcium in people 65 to 85, run by Vanderbilt University Medical Center. It plans to enroll about 90 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 85. Conditions: Type 2 Diabetes Mellitus (T2DM); Sarcopenia; Obesity; Muscle Loss; Older Adults.
Age 65 to 85 years, inclusive.
Type 2 diabetes mellitus, defined by HbA1c at or above 6.5% or current use of antihyperglycemic medication.
Body mass index at or above 27 kg/m2.
Newly initiating semaglutide as standard clinical care under the direction of a treating clinician.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Calcium-HMB Plus Vitamin D3; Matching placebo
Registered summary
This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants will receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07621497
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Phase 2
Sun Yat-sen University
About 229 people
Starts Nov 1, 2026 (estimated)
In plain words A Phase 2 study of calcium in people 18 and older, run by Sun Yat-sen University. It plans to enroll about 229 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Metastatic Colorectal Cancer (CRC).
Age ≥ 18 years, male or female.
ECOG performance status 0-2.
Histologically or cytologically confirmed unresectable metastatic colorectal cancer with no prior treatment for unresectable or metastatic disease.
Adequate organ function: Hb ≥ 70 g/L; WBC ≥ 3.0×10⁹/L; NEUT ≥ 1.5×10⁹/L; PLT ≥ 75×10⁹/L; AST and ALT ≤ 3× ULN; sCr ≤ 2× ULN; TBIL ≤ 2× ULN.
1 more inclusion criterion and the exclusion criteria are on the listing.
This is a prospective, multicenter, randomized controlled, phase II study. It is expected to enroll 229 patients and aims to evaluate the efficacy and safety of FOLFOX8 versus mFOLFOX6 combined with bevacizumab or cetuximab as first-line treatment for unresectable metastatic colorectal cancer. The primary objective is to assess progression-free survival (PFS) of the patients. Secondary objectives include assessment of objective response rate (ORR), overall survival (OS), safety, and other outcomes.
Where, as registered
No US site; China (3).
Not yet recruitingNCT07772609
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Phase 4
Sahlgrenska University Hospital
About 216 people
Starts Jan 11, 2027 (estimated)
In plain words A Phase 4 study of calcium in female participants 60 and older, run by Sahlgrenska University Hospital. It plans to enroll about 216 people at 9 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 60 and older. Conditions: Osteoporosis in Post-menopausal Women.
The subject is a postmenopausal woman aged 60 years or older at screening.
The subject has provided written informed consent before any trial-specific procedure is performed.
The subject has osteoporosis at screening defined as a T-score of -2.5 or lower at the total hip or lumbar spine (L1-L4) on central reader confirmed bone densitometry by DXA.
The subject is at high fracture risk, defined by at least one of the following: a previous low-trauma fracture after age 50 years (excluding skull, face, fingers and toes); FRAX probability at or above the age-specific Swedish intervention…
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Romosozumab; Zoledronic Acid 5 MG in 5 ML Injection; Calcium 500 mg and Vitamin D3 800 IU; Denosumab
Registered summary
Osteoporosis is associated with a high risk of fractures, disability, loss of independence, and excess mortality. Zoledronic acid is an established first-line treatment in Sweden, but many patients at high fracture risk remain at substantial residual fracture risk. Short-course treatment with romosozumab followed by denosumab produces large increases in bone mineral density, but has not been directly compared with zoledronic acid. The full summary is on the listing.
Where, as registered
No US site; Sweden (9).
Not yet recruitingNCT07865429
Efficiency of Calcium Hydroxide and Calcium Silicate-Based Sealers in Maxillary and Mandibular Molars on Post-Root Canal Pain
No phase
Dow University of Health Sciences
About 96 people
Starts Oct 15, 2026 (estimated)
In plain words A study of calcium in people 18 to 45, run by Dow University of Health Sciences. It plans to enroll about 96 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45. Conditions: Calcium Silicate Based Sealer (CSBS).
Medically healthy patients
Age: 18 to 45 years
Vital Pulp with moderate to severe pre-operative pain score (VAS score 4-10 on EPT).
Symptomatic apical periodontitis
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Calcium silicate based sealer
Registered summary
patients reported at department of Operative dentistry diagnosis section , patients coming to operative department of DIDC-DUHS with the chief complain of moderate to severe pain will be assessed .Complete history of each patient will be obtained along with clinical examination including percussion test, presence of swelling, sinus tract and mobility of tooth. Pulp sensitivity will be assessef. Periapical x-ray will be used to evaluate periapical status PAI score. . Following anesthesia, the tooth will be isolated with a rubber dam to maintain a dry operating field. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
Not yet recruitingNCT06820645
Calcium Administration in Life-saving Management During Massive Hemorrhage
Phase 2 and 3
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
About 81 people
Starts May 1, 2025 (estimated)
In plain words A Phase 2 and 3 study of calcium in people 18 and older, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. It plans to enroll about 81 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Massive Hemorrhage; Trauma; Hypocalcemia.
Adult trauma patients undergoing the MHP at Victoria Hospital, London, Ontario
The exclusion criteria are on the listing.
What it tests, as registered
calcium gluconate; Control: Placebo
Registered summary
This study evaluates the feasibility of conducting a larger study on the impact of treating massive hemorrhage with calcium in trauma patients. Patients undergoing the Massive Hemorrhage Protocol (MHP) will be randomly assigned to receive either calcium gluconate or placebo drug after every 4 packs of units of RBCs received during the MHP.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06648525
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Phase 2
Harbin Medical University
About 68 people
Starts Oct 2024 (estimated)
In plain words A Phase 2 study of calcium in people 18 to 75, run by Harbin Medical University. It plans to enroll about 68 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Intrahepatic Cholangiocarcinoma (Icc).
Age: 18 to 75 years old, male or female not limited;
Histologically confirmed unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma with measurable tumor lesions (meeting RECIST 1.1 criteria);
Have not received systemic anti-tumor treatment in the past;
Patients who relapse more than 6 months after curative surgery or after completion of adjuvant therapy (chemotherapy and/or radiotherapy) meet the inclusion criteria;
3 more inclusion criteria and the exclusion criteria are on the listing.
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).
Where, as registered
No US site; China (1).
Not yet recruitingNCT07861867
AKG and Brain Health in Aging
Phase 2
University of Oklahoma
About 60 people
Starts Feb 1, 2027 (estimated)
In plain words A Phase 2 study of calcium in people 55 and older, run by University of Oklahoma. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 55 and older; healthy volunteers accepted. Conditions: Brain Aging; Cerebrovascular Function.
Age ≥55 years
Adequate hearing and visual acuity to participate in the examinations (with or without aids)
Ability to read and write in English
Competence to provide informed consent
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Calcium AKG; Oral placebo capsules
Registered summary
This proposal will test the hypothesis that AKG supplementation will improve NGVC responses and cognitive performance in older adults. We will also test the hypothesis that these effects are mediated by a decrease in age-related oxidative stress within NGVU cells.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07773805
Clinical and Radiographic Success of Calcium Hydroxide-Iodoform Paste Versus Modified Triple Antibiotic Paste for Necrotic Primary Molars in Children
No phase
Cairo University
About 50 people
Starts Jan 2027 (estimated)
In plain words A study of calcium in people 4 to 7, run by Cairo University. It plans to enroll about 50 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 7. Conditions: Dental Pulp Necrosis; Periapical Diseases; Dental Caries; Primary Teeth.
Pediatric patients aged 4-7 years
Positive parental informed consent
Restorable necrotic mandibular second primary molars with peri-radicular/furcal involvement and/or pathologic root resorption (external or internal one-third to two-thirds of the root)
Presence of chronic apical abscess or sinus tract or furcation radiolucency
This randomized clinical trial aims to compare the clinical and radiographic success of calcium hydroxide-iodoform paste and modified triple antibiotic paste when used for the treatment of necrotic primary molars in children using the lesion sterilization and tissue repair (LSTR) technique. The study will include children aged 4-7 years with restorable necrotic mandibular second primary molars. Participants will be randomly assigned to receive LSTR treatment with either calcium hydroxide-iodoform paste or modified triple antibiotic paste. The full summary is on the listing.